Idiopathic pulmonary fibrosis (IPF) is a progressive scarring disease of the lungs. It is serious, it is irreversible with any therapy now available, and most people reading this page already know that.
This article sets out what mesenchymal stem cell (MSC) therapy is being studied for in IPF, what the human trials have and have not shown, and — just as importantly — what else is available to you that has stronger evidence behind it than anything on this page.
⚠️ Read this first. MSC therapy for IPF is research, not treatment. Three small human trials have been published: two phase 1 safety studies and one randomised study of twenty patients [10][11][12]. No phase 3 trial exists. Meanwhile, antifibrotic drugs, pulmonary rehabilitation, transplant referral, symptom treatment and palliative care all have stronger evidence than MSC therapy does, and several of them are time-critical. They are covered on this page, and if you read only one section, read What Else Is Available.
The Problem: When Every Breath Becomes a Struggle
Imagine walking to your mailbox and needing to stop halfway to catch your breath. For patients with pulmonary fibrosis, this scenario is daily reality. The disease causes progressive scarring of lung tissue, making it increasingly difficult for oxygen to pass into the bloodstream.
The Patient Experience
The journey typically begins subtly—a dry, persistent cough that won't go away, gradually worsening shortness of breath during activities that were once effortless. Simple tasks like climbing stairs, showering, or carrying groceries become exhausting endeavors. As the disease advances, many patients require supplemental oxygen, tethering them to tanks and limiting their independence.
The emotional toll is equally significant. The knowledge that conventional treatments offer only partial slowing of progression—never reversal—creates profound anxiety. Patients watch their pulmonary function tests decline month after month, feeling powerless against the disease's march.
Understanding Pulmonary Fibrosis
What Is Pulmonary Fibrosis?
Pulmonary fibrosis refers to a group of lung disorders characterized by the formation of scar tissue (fibrosis) within the interstitium—the tissue and space around the air sacs (alveoli) of the lungs. This scarring thickens the lung tissue, reducing its ability to transfer oxygen to the blood.
Idiopathic Pulmonary Fibrosis (IPF)
When the cause is unknown, the condition is termed "idiopathic." IPF is the most common and severe form of idiopathic interstitial pneumonia [1]. Diagnosis follows international criteria based on high-resolution CT pattern and, where needed, histopathology, assessed by a multidisciplinary team [4]. The word "idiopathic" means "of unknown cause," reflecting the medical community's incomplete understanding of what triggers the disease in most patients.
Current Standard Treatments
The therapeutic landscape for IPF has evolved considerably over the past decade, and current management is set out in the 2022 ATS/ERS/JRS/ALAT clinical practice guideline [4]. Two antifibrotic medications are now approved for treatment:
Pirfenidone works by reducing fibroblast proliferation and collagen synthesis, while nintedanib is a tyrosine kinase inhibitor that targets multiple growth factor pathways involved in fibrosis. These two drugs are the only approved disease-modifying therapies in IPF, and their trial results are the most solid numbers on this page:
- ASCEND (pirfenidone, 555 patients, 52 weeks): a 47.9% relative reduction in the proportion of patients who had a ≥10 percentage-point decline in predicted FVC or died [2]. ⚠️ In that trial there was no significant difference in breathlessness scores (p=0.16) or in death from any cause (p=0.10); the survival benefit reached significance only in a pooled analysis with two earlier trials.
- INPULSIS (nintedanib, 1,066 patients, two replicate trials): annual FVC decline of −114.7 mL versus −239.9 mL on placebo (difference 125.3 mL, 95% CI 77.7-172.8), and −113.6 versus −207.3 mL (difference 93.7 mL, 95% CI 44.8-142.7) [3].
⚠️ "Approximately 50%" refers to the rate at which lung function declines — not to the disease as a whole, and not to survival. It is a real and worthwhile effect, and it is larger and far better established than anything published for stem cells in this disease.
However, these drugs do not:
- Reverse existing scarring
- Restore lost lung function
- Cure the underlying disease
- Work effectively for all patients
Lung Transplantation — and Why the Timing Is the Part That Matters
Lung transplantation is the only intervention shown to extend survival in IPF.
⚠️ The decision that determines whether you ever get one is made early, and it is not made by you. International consensus is that people with IPF should be referred for transplant assessment at the time of diagnosis, or as soon as lung function begins to decline — not when the disease becomes advanced [13]. IPF is unpredictable and can deteriorate faster than an assessment can be completed. Late referral is a recognised cause of death on the waiting list.
Being referred does not commit you to a transplant. It starts a process that takes months, and it preserves an option you cannot recover once it is gone.
If you have IPF and have not been referred, ask your pulmonologist why at your next appointment. Age alone is not an automatic barrier — centres assess individually [13].
Donor availability, surgical risk and lifelong immunosuppression are real limitations, and transplant is not right for everyone. None of them is a reason to delay the conversation.
The Biology of Fibrosis: Aberrant Wound Healing
Understanding how pulmonary fibrosis develops helps explain why regenerative approaches show promise. In healthy lungs, injury triggers a coordinated healing response: inflammation resolves, damaged tissue is cleared, and normal architecture is restored. In IPF, this process goes awry.
The Fibrotic Cascade
The disease process involves several interconnected mechanisms:
1. Repeated Micro-Injury
The alveolar epithelium—the delicate lining of the air sacs—suffers repeated damage, possibly from environmental exposures, genetic factors, or aging-related changes. This triggers chronic activation of repair mechanisms.
2. Fibroblast Activation
Fibroblasts, the cells responsible for producing connective tissue, become inappropriately activated. They transform into myofibroblasts—cells with contractile properties that secrete excessive amounts of collagen and other extracellular matrix proteins.
3. Transforming Growth Factor-β (TGF-β) Signaling
TGF-β is a key cytokine driving fibrosis. In IPF, TGF-β signaling becomes dysregulated, continuously stimulating fibroblast activation and collagen deposition while suppressing normal epithelial repair.
4. Disrupted Immune Regulation
The immune system plays a complex role in IPF. Rather than appropriately resolving inflammation, immune cells contribute to ongoing tissue damage and aberrant repair.
The result is progressive architectural distortion of the lungs—stiff, scarred tissue replacing the thin, elastic membranes essential for gas exchange.
What the Research Says: MSC Mechanisms and Evidence
Mesenchymal stem cells are being studied in IPF because of properties observed in laboratory and animal work.
⚠️ Read the next two sections with one fact in mind: almost everything in them comes from mice and cell cultures. Each mechanism below is labelled with the evidence it rests on. A mechanism demonstrated in a mouse is a reason to run a trial. It is not a reason to expect a result in a person — the bleomycin mouse model of lung fibrosis has produced many effects that did not reproduce in humans.
Anti-Inflammatory Properties
MSCs possess potent immunomodulatory capabilities. They can:
- Suppress T-cell proliferation and activation
- Modulate macrophage phenotype from pro-inflammatory (M1) to anti-inflammatory (M2)
- Reduce levels of pro-inflammatory cytokines including TNF-α and IL-6
- Increase production of anti-inflammatory mediators like IL-10⁶
Evidence class: cell culture. Reference 6 is an in vitro study of MSC effects on alveolar epithelial cells.
These effects help create a more favorable environment for tissue repair while dampening the chronic inflammation that drives fibrosis progression.
Anti-Fibrotic Mechanisms
Research demonstrates multiple pathways through which MSCs counteract fibrosis:
TGF-β Modulation: MSCs can reduce TGF-β signaling, counteracting a primary driver of fibroblast activation and collagen deposition [7]. Evidence class: mouse. Reference 7 studied human umbilical-cord MSCs in bleomycin-injured mouse lung.
Fibroblast Regulation: MSCs inhibit fibroblast proliferation and their transformation into myofibroblasts [8]. Evidence class: mouse. Reference 8 is a bleomycin mouse study from 2003.
Matrix Remodeling: MSCs produce matrix metalloproteinases and their inhibitors, which may help balance extracellular matrix production and degradation [6]. Evidence class: cell culture.
Paracrine Signaling and Extracellular Vesicles
MSC effects are thought to occur largely through paracrine mechanisms—secretion of bioactive molecules including growth factors, cytokines and extracellular vesicles (exosomes) [5]. Evidence class: review of preclinical work. In laboratory and animal models these signalling molecules:
- Promote epithelial cell survival and regeneration
- Enhance angiogenesis (new blood vessel formation)
- Reduce apoptosis (programmed cell death) in lung tissue
Mitochondrial Transfer
One proposed mechanism involves transfer of mitochondria from MSCs to damaged lung cells, restoring energy production in injured epithelial cells [9].
⚠️ Evidence class: mouse, and a different disease. Reference 9 studied acute lung injury in mice — a sudden, inflammatory, potentially reversible insult. IPF is chronic progressive fibrosis. Mitochondrial transfer in acute injury is not evidence of benefit in fibrosis, and this page should not have implied it was.
Clinical Trial Evidence
Three trials of MSC therapy in IPF have been published. Together they total 37 patients. All three are set out below in full, including the parts that are unfavourable.
AETHER — phase I, 9 patients (2017)
The AETHER trial tested bone marrow-derived allogeneic MSCs, given as a single intravenous infusion at 20, 100 or 200 million cells, in nine patients with mild-to-moderate IPF [10].
- This was a phase I trial and its primary endpoint was safety — the incidence of treatment-emergent serious adverse events at week 4.
- Result: there were none. ⚖️ In a disease this serious, that is a real and reassuring finding, and it deserves to be stated plainly rather than buried.
- Two patients died during the study. Both deaths were from progression of IPF and were assessed as unrelated to treatment.
- At 60 weeks, the group showed a mean decline of 3.0% predicted FVC and 5.4% predicted DLCO.
- ⚠️ Those decline figures cannot be compared with the antifibrotic trials above. There were nine patients, no control group and no blinding. The authors' own conclusion was that the data "support the safety of a single infusion" — safety, not efficacy.
Chambers — phase 1b, 8 patients (2014)
Eight patients with moderately severe IPF received placenta-derived MSCs intravenously [11].
- Well tolerated, with only minor and transient effects; a temporary 1% fall in blood oxygen saturation 15 minutes after infusion.
- At six months, FVC, DLCO, six-minute walk distance and CT fibrosis score were all unchanged from baseline, with no evidence of worsening fibrosis.
- ⚠️ This trial had no control group and was not randomised. IPF declines over time, so stability looks like benefit — but with eight patients and no comparator, it cannot be shown to be.
- ⚠️ The authors noted that MSCs "may be profibrotic in some circumstances." That is a caution about this therapy in this disease, from the people who ran the trial, and you should have it.
Averyanov — randomised, 20 patients (2020)
The only randomised, placebo-controlled trial. Twenty patients with rapidly progressing moderate-to-severe IPF received either bone marrow-derived allogeneic MSCs or placebo [12].
- The MSC group did significantly better than placebo for six-minute walk distance at 13 weeks, DLCO at 26 weeks and FVC at 39 weeks.
- At 12 months, FVC had risen 7.8% from baseline in the MSC group and fallen 5.9% in the placebo group.
- No significant adverse effects.
- ⚠️ There was no difference in mortality — two patients died in each group.
- ⚠️ CT fibrosis scores did not change in either group. The scarring itself was not reduced.
- ⚠️ Twenty patients, and no confidence intervals were reported. This is a first-in-human dosing study, not a phase 3 result.
⚠️ The dose in that trial is the part to pay attention to. Averyanov's patients received 200 million cells every three months, to a cumulative total of 1.6 billion cells each. That is roughly sixteen times the total dose in a single 100-million-cell infusion. The one trial that reported a functional benefit used a regimen that commercial single-infusion programmes — including this one — do not provide.
What none of these trials showed
- No trial reported any patient reducing or discontinuing supplemental oxygen.
- No trial reported reversal of fibrosis on imaging. Two measured it; neither found it.
- No trial showed a survival benefit.
- No phase 3 trial of MSC therapy in IPF has been completed. Until one is, this remains research.
⚠️ And one substitution you should know about before deciding anything. Every human trial above used bone marrow or placenta-derived cells. This clinic uses umbilical cord-derived cells. There is no published human trial of umbilical-cord MSCs in IPF. The umbilical-cord evidence that exists is reference 7 — a mouse study. Cell source is not a detail; it is the product.
Treatment Options Compared
What Else Is Available — and When It Is Time-Critical
⚖️ This section exists because the rest of this page is about one unproven therapy, and a person with IPF deserves the whole picture. Everything below has stronger evidence behind it than MSC therapy does, and several items are time-sensitive.
⚠️ Know the signs of an acute exacerbation — this is the emergency
An acute exacerbation is a sudden, unexplained worsening of breathlessness, usually over days to a few weeks, sometimes with cough or fever. It is one of the leading causes of death in IPF and it is a medical emergency.
If your breathing gets suddenly and significantly worse over days, seek urgent medical assessment. Do not wait to see whether it settles, and do not attribute it to any treatment you have had.
This matters on this page specifically: elsewhere you will read that cellular effects unfold over "weeks to months". That timeline is about a treatment response. It is not a reason to wait out a sudden deterioration.
Pulmonary rehabilitation
A Cochrane review of 21 studies found that pulmonary rehabilitation improves six-minute walk distance in interstitial lung disease by 40.07 metres (95% CI 32.70-47.44) across 585 participants, with moderate-certainty evidence. In the IPF subgroup specifically, the improvement was 37.25 metres (95% CI 26.16-48.33) across 278 participants [14].
⚠️ That is a larger, better-replicated and better-controlled functional result than anything published for MSC therapy in this disease — and it is usually available through your existing respiratory service.
Treatment for cough
Chronic cough is one of the most disabling IPF symptoms and is often dismissed. There is now randomised evidence for treating it: in a placebo-controlled crossover trial, low-dose controlled-release morphine reduced objective daytime cough frequency by 39.4% (95% CI −54.4 to −19.4, p=0.0005) [16]. ⚠️ Side effects were more common on morphine (40% vs 14%), mainly nausea and constipation. It is worth asking your respiratory team about.
Palliative care — earlier than you think
Palliative care is not hospice and not a decision to stop treatment. It is specialist help with breathlessness, cough, fatigue, anxiety and planning, delivered alongside everything else. The European Respiratory Society has published a clinical practice guideline on integrating it into care for people with ILD [15].
⚠️ Being honest about the state of this evidence: the one randomised trial of palliative care specifically in IPF was a 22-patient pilot and did not show improvement in quality of life scores. The recommendation to integrate palliative care rests on guideline consensus and evidence from related conditions, not on a positive IPF trial. It is offered here as a reasonable option, not as a proven one.
Oxygen, vaccination, and smoking
- Supplemental oxygen relieves breathlessness and supports exercise tolerance. It does not treat the disease — and it is not a failure or a last resort. Use it as prescribed.
- Vaccination (influenza, pneumococcal, COVID-19) is standard supportive care in fibrotic lung disease, because respiratory infection can precipitate deterioration.
- If you smoke, stopping is the single most valuable thing you can do for your lungs, at any stage.
New drugs, and clinical trials
IPF drug development is active and it fails often — which is the honest context for any unproven therapy. Recent examples in both directions: nerandomilast, an oral antifibrotic, met its primary endpoint in a phase 3 trial of 1,177 patients, with FVC declining 114.7 mL versus 183.5 mL on placebo (difference 68.8 mL, 95% CI 30.3-107.4) [17]. Other candidates have failed outright at phase 3.
⚠️ Enrolling in a clinical trial is a real option and it is usually free. It gives you access to therapies under monitored conditions, and it generates the evidence that patients after you will need. Ask your pulmonologist what is recruiting.
Is This Right For You? Candidacy Considerations
⚠️ Before this section is useful, two things need to be true, and neither is about stem cells:
- You have been referred for transplant assessment, or have discussed with your pulmonologist why you have not been. Not "you are not a candidate" — referred, and assessed. This page is not a place to decide you are ineligible for the only treatment that extends survival [13].
- You are on antifibrotic therapy, or have discussed with your specialist why you are not. Pirfenidone and nintedanib are the only approved disease-modifying drugs [2][3]. MSC therapy is not an alternative to them and should never be a reason to delay or stop them.
With those in place, MSC therapy is research that some patients choose to pursue. It may be considered by people who:
- Have a confirmed diagnosis of IPF or another form of pulmonary fibrosis
- Have early to moderate disease with better preserved lung function
- Are continuing their standard care, including antifibrotics if prescribed
- Understand that this is phase 1/2 research, that no trial has shown a survival benefit, and that complete reversal is unlikely
- Understand that the cost is theirs and that a clinical trial may offer monitored access to cell therapy at no charge
Important Realistic Expectations
Patients considering regenerative therapy should understand:
Early Stage: Patients with mild-to-moderate impairment may experience stabilization of lung function and potential modest improvements in exercise tolerance.
Advanced Disease: While MSCs may still provide anti-inflammatory benefits, extensive established fibrosis is unlikely to be significantly reversed. Goals may shift toward slowing further progression and improving quality of life.
Timeline: Unlike pharmaceutical interventions with immediate dosing, regenerative approaches may require weeks to months for full effects to manifest as cellular mechanisms unfold.
The Sterling-Certified Approach
Sterling-certified partner clinics have developed a comprehensive protocol designed to maximize the potential benefits of regenerative therapy for people with pulmonary fibrosis.
Our 7-Day Core Protocol
Day 1: Preparation and Optimization
- Comprehensive Blood Panel: Detailed assessment to identify any factors that could compromise treatment response, and to confirm suitability for infusion
⚠️ Exosome and NAD+ infusions are offered by some programmes as "preparation" before cell therapy. There is no evidence that either improves the outcome of MSC treatment, and they are not part of any published IPF trial protocol. They are bundled into the package price, so declining them does not reduce what you pay. Ask what published evidence supports any therapy included in your protocol.
Day 2+: Core Regenerative Treatment
- 100 Million UC-MSCs: Umbilical cord-derived mesenchymal stem cells are available immediately, without the culture period that autologous cells require, and donor cells are not affected by the recipient's age
- Cell viability is released at 95% or above — fresh, not frozen. ⚠️ Viability is a release specification: it describes the cells that leave the laboratory. It is not a measure of clinical potency, which in cell therapy requires a validated assay that has not been published for this product
- Full Certificate of Analysis documenting your specific cell batch
- ⚠️ No published human trial in IPF has used umbilical cord-derived cells. The three trials described above used bone marrow or placental cells [10][11][12]
- IV Administration: Stem cells are delivered intravenously, allowing them to circulate to the lungs and exert systemic immunomodulatory effects
Days 3-7: Recovery and Optimization
- Follow-up assessments
- Supplementary supportive therapies as indicated
- Personalized recommendations for home care
Premium Add-On Therapies
⚠️ Additional therapies are offered by the partner clinics — NK/NKT cell therapy, plasmapheresis, cord blood plasma and immunokine therapy among them. None of them has published evidence in idiopathic pulmonary fibrosis. They are not part of any IPF trial protocol described on this page, and none of them is defined or priced in the clinic's own canonical package document — so ask what each one costs and what it includes, in writing, before agreeing to it.
⚠️ NK/NKT cell therapy in particular requires a 21-28 day stay abroad for cell culturing. For someone with progressive fibrotic lung disease, that is a substantial commitment of remaining time, travel and money, for a therapy with no evidence in this condition.
If any add-on is recommended to you, ask what published evidence supports it in pulmonary fibrosis specifically. You are entitled to a straight answer, and to decline.
What to Expect: A Realistic Timeline
Immediate (Days 1-7)
Most patients report feeling well during the treatment week. Some experience mild fatigue as the body processes the cellular therapies. The anti-inflammatory effects of exosomes and NAD+ may provide early symptomatic benefits for some individuals.
Short-Term (Weeks 2-8)
This period represents the initial cellular response phase. MSCs are homing to sites of inflammation, secreting paracrine factors, and beginning their immunomodulatory work. Some patients report improved energy levels and reduced breathlessness with activity.
Medium-Term (Months 3-6)
By this stage, the biological effects of MSC therapy are well underway. Follow-up pulmonary function testing may reveal stabilization of lung volumes and diffusion capacity. Quality of life measures often show improvement even when objective lung function changes are modest.
Long-Term (Months 6-12 and Beyond)
Sustained benefits may continue as the cellular environment remains modulated. Some patients may consider repeat treatments based on their response and disease progression. Regular monitoring with pulmonologists remains essential.
Setting Realistic Goals
It is essential to approach MSC therapy with appropriate expectations:
- Primary Goal: Slowing or halting disease progression
- Secondary Goal: Modest improvements in exercise tolerance and quality of life
- Tertiary Goal: Potential stabilization or minor improvement in pulmonary function parameters
Complete reversal of established fibrosis should not be expected. The value proposition lies in altering the disease trajectory and maintaining independence and quality of life for as long as possible.
Frequently Asked Questions
Q: Can stem cells cure my pulmonary fibrosis?
A: Currently, no therapy—including stem cells—can cure IPF or completely reverse established fibrosis. MSC therapy aims to slow disease progression and potentially provide modest functional improvements. Early intervention offers the best opportunity for meaningful benefit.
Q: How is this different from the medications my pulmonologist prescribed?
A: They are not in the same category, and the difference matters more than the mechanism. Pirfenidone and nintedanib are approved, prescribed, monitored, and proven in trials of hundreds to over a thousand patients [2][3]. MSC therapy is phase 1/2 research with 37 published patients in this disease.
MSC therapy is proposed to work through several mechanisms at once — reducing inflammation, modulating immune responses, supporting repair — but those mechanisms come from animal and laboratory work, not from human outcome data.
⚠️ MSC therapy is not a substitute for antifibrotic medication and must not be a reason to stop, reduce or delay it. If it is pursued at all, it is pursued alongside standard care, not instead of it.
Q: Are there any side effects?
A: ⚖️ Short-term safety is the best-established finding in this field, and it is genuinely reassuring. AETHER reported no treatment-emergent serious adverse events in nine patients [10]; Chambers reported only minor, transient effects in eight [11]; Averyanov reported no significant adverse effects in twenty [12]. Common effects are mild — temporary fever, fatigue, or infusion-site discomfort.
⚠️ Two limits on that reassurance. First, 37 patients across three trials is a small safety base, and uncommon risks would not be detected. Second, the Chambers investigators noted that MSCs "may be profibrotic in some circumstances" [11]— a theoretical concern that matters specifically in a fibrotic disease and has not been ruled out. Discuss individual risks with your pulmonologist.
Q: Will I be able to stop using oxygen?
A: Patients already dependent on supplemental oxygen are unlikely to discontinue its use after MSC therapy. ⚠️ No published trial has reported a single patient reducing or stopping supplemental oxygen after MSC treatment. The stated goal is to maintain current function; whether MSC therapy achieves even that has not been established in a controlled trial. Do not reduce prescribed oxygen on your own, and treat any claim that this therapy frees people from oxygen as a claim the evidence does not support.
Q: How soon will I know if the treatment is working?
A: Subjective improvements in energy and activity tolerance may be noticed within weeks. Objective measures through pulmonary function testing typically occur at 3-6 month intervals. The most meaningful assessment is comparing your trajectory before and after treatment.
Q: Can I have this treatment if I've already had a lung transplant?
A: Post-transplant patients require specialized immunosuppressive regimens. Any additional therapies must be carefully coordinated with the transplant team. MSC therapy would require individualized evaluation in this context.
Q: Why umbilical cord stem cells rather than using my own?
A: Umbilical cord-derived MSCs are highly proliferative, immediately available without a three-week culture period, and are not affected by the recipient's age — donor cell characteristics do genuinely decline with donor age, and a newborn donor avoids that.
⚠️ The honest limitation: no published human trial in IPF has used umbilical cord-derived cells. AETHER and Averyanov used bone marrow; Chambers used placenta [10][11][12]. The advantages above are logistical and biological arguments, not clinical results in this disease.
Q: What happens after the 7-day program?
A: Patients return home with aftercare instructions and should resume follow-up with their local pulmonologist, including continued antifibrotic therapy and routine lung function monitoring. ⚠️ Anything that changed about your prescribed medication should be reviewed by your own specialist.
⚠️ Sudden worsening of breathlessness over days is not a treatment response and should be assessed urgently — see the section on acute exacerbations above.